Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open

Today’s FDA decision on Abbisko’s pimicotinib (PIMJETMI / Beijiemai 贝捷迈) is a U.S. story. For overseas readers who want to understand China’s market—not the outbound license—the useful frame is the reverse: China was the first commercial market, Merck KGaA is the seller on the ground, and the bottleneck now is access inside Chinese hospitals and payment, not another Phase 3 headline.

This Desk note uses the same day’s Chinese industry coverage of the FDA approval as a prompt, then reads the China path that already ran ahead of it: NMPA approval, first prescriptions, early cash to Abbisko, local care patterns, and what is still missing on price and reimbursement.

What China already did

On 22 December 2025, China’s NMPA approved pimicotinib hydrochloride capsules (Beijiemai) for adults with symptomatic TGCT for whom surgical resection may cause functional limitation or relatively severe morbidity, as reported in Chinese regulator-facing coverage at the time. The marketing authorization applicant named in public Chinese notices was Merck Serono (Beijing)—not Abbisko as the China seller—consistent with the December 2023 license that put China commercial rights with Merck KGaA, which Abbisko’s HKEX announcement on the NMPA approval also reflects.

Process markers that matter for China diligence, per Abbisko’s HKEX NMPA note:

• Class 1 innovative chemical drug; reviewed under priority review.
• Roughly six months from NDA acceptance to approval, described by Abbisko as a zero-deficiency (“零发补”) outcome.
• During review, China’s CFDI ran what Abbisko called its first overseas clinical-site inspection for this program—and cleared it.

In other words: China did not wait for FDA. For a rare orthopedic oncology niche, Beijing became the launch market and the first proof that a China-origin CSF-1R asset could clear domestic review with a multinational as commercial partner.

Hospitals and channels: where a China launch actually starts

TGCT care in China is still surgery-first. Chinese expert consensus and later CSCO-facing commentary describe active observation, surgery, radiation, and drugs as options, with MDT decisions for difficult diffuse disease; for unresectable TGCT, CSF-1/CSF-1R pathway inhibition is the preferred systemic approach once a drug exists.

That is why the early commercial map is orthopedic / bone-tumor hospitals, not a broad GP footprint:

• March 2026: Beijing Jishuitan Hospital wrote what Merck/Abbisko communications call the world’s first Beijiemai prescription; early batches also appeared at Sun Yat-sen University First Affiliated Hospital, Peking University Third Hospital, and sites in Zhejiang.
• April 2026: Alibaba Health announced a nationwide online first listing—a typical China parallel track for specialty oral drugs: tertiary hospital Rx plus internet pharmacy fulfillment—as covered in Xinhua/Alibaba Health reporting at the time.
• TGCT sits on China’s second national rare-disease catalog, which helps policy visibility but does not by itself equal automatic reimbursement.

For overseas commercial teams, the translation is simple: early volume concentrates in a handful of referral centers that already run soft-tissue / bone tumor MDTs. National “coverage” is secondary until those centers adopt the product into pathways and pharmacy lists.

Pricing and reimbursement: what is—and is not—on the record

Public company and regulator materials around the China approval and first prescriptions emphasize indication, clinical data, and hospital uptake. They do not, in the public materials reviewed for this note, publish a national list price or confirm NRDL (national reimbursement drug list) inclusion.

That gap is itself the China-market signal:

1. Launch phase = hospital access + self-pay / commercial insurance / assistance programs until a national or provincial reimbursement decision lands.
2. Rare-disease labeling and catalog status raise the political case for later negotiation; they are not a substitute for an NRDL deal.
3. Cash already moved on China commercial activity. In June 2026, Abbisko’s HKEX-linked disclosure reported receiving about USD 13.52 million from Merck covering the milestone tied to China’s first prescription plus Q1 2026 sales royalties—evidence that China sales had begun, not that reimbursement was solved.

Desk watchlist for the next China payment read: whether Beijiemai enters NRDL negotiation materials, any provincial temporary reimbursement, published hospital procurement prices, and Merck’s patient-support framing.

Local competition: surgery still rules; Beijiemai is the first systemic Class 1

Inside China, the incumbent “competitor” is not another branded CSF-1R on the shelf—it is repeat surgery. Pre-drug Chinese real-world commentary around diffuse TGCT has stressed near-total reliance on operations and almost no systemic therapy when no approved option existed.

On the drug side:

• Beijiemai is repeatedly described in Abbisko/Merck China launch communications as China’s first (and, at launch, only) Class 1 innovative drug approved for systemic TGCT treatment.
• Global CSF-1R peers such as pexidartinib (Turalio) are discussed in Chinese consensus literature mainly as overseas reference products with hepatotoxicity baggage; they were not the China-approved standard at Beijiemai’s launch.
• Chinese pipeline names historically cited in TGCT (for example other CSF-1R programs from domestic innovators) remain longer-horizon competitive risk, not same-shelf rivals today.
• Guideline/consensus language has moved quickly once a drug existed: CSF-1R inhibitors as preferred systemic therapy for unresectable disease, and later CSCO-facing updates elevating pimicotinib on the strength of MANEUVER plus China approval.

Competitive takeaway for BD: China share in the near term is about displacing surgical cycles and capturing MDT protocols, not winning a three-brand formulary fight.

How overseas practitioners should read today’s FDA news from a China lens

• Do not reverse the chronology. China approved first (Dec 2025), wrote first Rx (Mar 2026), and already paid an Abbisko China-commercial milestone before the U.S. label (Nov 2026).
• Ask “who sells in China?” Merck holds commercial rights; Abbisko’s China economics are milestones and royalties. That is a different diligence file from Abbisko building a China specialty sales force.
• Separate hospital launch from reimbursement. Named tertiary centers + online pharmacy listing = access starting line. NRDL / provincial payment is the volume and durability question still open in public materials.
• Benchmark local competition correctly. Until another CSF-1R clears NMPA, the China battle is protocol change versus surgery and center-by-center pharmacy adoption.

Limits

This is industry analysis built from today’s Chinese FDA coverage plus public China approval, hospital, and HKEX disclosures. It is not a price forecast, formulary status certificate, or clinical guidance. Exact list prices and NRDL status should be verified against the latest NHSA / hospital notices before any commercial model is locked.

China Pharma Desk analysis. Industry information only—not medical or investment advice.